In China, gene testing technology is rapidly integrating into oncology treatment processes, advancing precision medicine from concept to clinical practice. According to the latest data from the National Cancer Center, in 2023, over 30% of newly diagnosed cancer patients in China received at least one gene test, nearly doubling the rate from five years ago. This trend is particularly prominent in large tertiary hospitals, such as Fudan University Shanghai Cancer Center and Peking Union Medical College Hospital, where gene testing coverage for lung cancer and breast cancer patients exceeds 70%.
The widespread adoption of gene testing has directly promoted the rational use of targeted drugs. Taking non-small cell lung cancer as an example, the increased detection rate of driver genes such as EGFR and ALK has improved the treatment efficacy of targeted drugs like osimertinib and crizotinib by approximately 40%, extending the median progression-free survival to over 18 months. Additionally, advances in liquid biopsy technologies, such as ctDNA testing, enable patients who cannot obtain tissue samples to receive precise molecular subtyping, further expanding the beneficiary population.
Background and Significance
Cancer treatment in China is shifting from a "one-size-fits-all" approach to "individualized" care, driven primarily by the declining cost of gene sequencing and the maturation of bioinformatics analysis. Over the past decade, the cost of whole-genome sequencing has dropped by 99%, and domestic policies such as "Healthy China 2030" explicitly support the development of precision medicine. In 2024, the National Medical Products Administration approved multiple domestically produced gene testing kits covering key targets such as BRCA and MSI, providing more convenient tools for clinical use.
The significance of precision treatment lies not only in improving efficacy but also in reducing ineffective treatments. For example, by testing RAS gene status, colorectal cancer patients can avoid the use of ineffective cetuximab, saving medical resources and reducing side effects. This data-driven decision-making model is becoming the new standard for cancer treatment in China.
Significance for International Patients
For international patients seeking overseas medical care, China's precision oncology treatment offers a cost-effective option. Compared to Europe and the United States, gene testing and targeted therapy in China cost 30%-50% less, with shorter waiting times. For instance, a comprehensive genomic analysis covering 300 genes costs approximately 8,000 RMB (about 1,100 USD) in China, while the same test in the United States exceeds 5,000 USD. Moreover, Chinese clinicians have accumulated extensive experience in managing resistance to targeted drugs, providing a complete treatment chain.
More importantly, China participates in multiple international multicenter clinical trials, allowing patients early access to cutting-edge drugs. For example, the ongoing CAR-T cell therapy trial for solid tumors at Shanghai Ruijin Hospital has attracted several overseas patients. Through the Medical Services section, international patients can schedule expert consultations and use the Cost Estimator tool to understand treatment budgets.
How Meijiakang Helps
As a cross-border medical platform, Meijiakang is dedicated to helping international patients access China's top-tier precision oncology treatment resources. We have established green channels with partner hospitals such as Fudan University Shanghai Cancer Center and Zhongshan Hospital, providing one-stop services from gene testing to targeted therapy. Specifically, we assist patients in arranging cross-border logistics for test samples, ensuring delivery to the laboratory within 24 hours; our professional medical translation team interprets gene reports and arranges multidisciplinary consultations; and we coordinate subsequent treatments, such as targeted drug procurement or clinical trial enrollment.
Additionally, our Contact Us page provides 24/7 online support, where patients can access the latest treatment guidelines and hospital schedules. Meijiakang also offers personalized follow-up plans to ensure long-term post-treatment management. We commit to transparent pricing for all services with no additional markup, allowing patients to focus on recovery.
Related Reading: Overview of Shanghai Partner Hospitals